替吉奥联合顺铂新辅助化疗治疗胃癌疗效观察

Curative efficacy observation of neo-adjuvant chemotherapy of gimeracil and oteracil porassium capsules combined with cisplatin in the treatment of patients with gastric cancer

目的探讨替吉奥联合顺铂新辅助化疗治疗胃癌的疗效。方法 60例符合纳入标准的胃癌患者随机分为观察组与对照组各30例。对照组给予顺铂+手术治疗,观察组给予替吉奥+顺铂+手术治疗。观察、比较2组患者术前化疗近期疗效及手术切除状况。结果观察组客观有效率为60.0%,对照组客观有效率为56.7%,2组比较差异无统计学意义(P>0.05)。观察组行根治切除术例数明显多于对照组,行姑息性切除术和探查术的例数明显少于对照组。比较差异均有统计学意义(P<0.05)。结论替吉奥联合顺铂新辅助化疗治疗胃癌可以提高患者行根治切除术的机会,从而提高患者的长期生存率。

Objective To investigate the curative efficacy of neo-adjuvant chemotherapy of gimeracil and oteracil porassium capsules combined with cisplatin in the treatment of patients with gastric cancer. Methods 60 cases of gastric cancer patients meeting the inclusion criteria were randomly divided into observation group and control group,each of 30 cases. The control group was treated with cisplatin in combination with surgery,while the observation group was treated with gimeracil and oteracil potassium capsules and cisplatin in combination with surgery. The short term effective rate and operation resection status of the 2 groups were observed and compared. Results The short term effective rate of the observation group was 60%,and that of the control group was 56. 7%,the difference between 2 groups was not statistically significant. The number of patients received radical resection in the observation group were significantly more than that in control group,and the number of patients received palliative resection and surgical exploration was significantly less than that of the control group,the differences were statistically significant（ P〈0. 05）. Conclusion The neo-adjuvant chemotherapy of gimeracil and oteracil porassium capsules combined with cisplatin can improve the patients＇ chance of undergoing radical resection,so then improve the long-term survival rate of patients.